Navigation Links
Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
Date:11/12/2012

PISGAH FOREST, N.C., Nov. 12, 2012 /PRNewswire/ -- Pisgah Laboratories, Inc. (www.pisgahlabs.com) has recently received three Notices of Allowance for United States Patents related to its abuse deterrent medications platform. Earlier this year, Pisgah obtained US Patent 8,211,905 emanating from work conducted at their facility in Pisgah Forest, NC. The latest Notices represent additional milestones to what Pisgah believes will be significant advances in the war on drug abuse. Two of the Notices relate to "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose-Dumping Properties," and the third is entitled, "Salts of Physiologically Active and Psychoactive Alkaloids and Amines Simultaneously Exhibiting Bioavailability and Abuse Resistance." Pisgah indicates these patent allowances are the foundation to what they expect to be a broad intellectual property portfolio encompassing narcotics, obesity treatment drugs, and high abuse-potential medications used to treat attention deficit hyperactivity disorder, AD(H)D.

Pisgah's approach to counter drug abuse is to re-vamp the chemistry of abused medications so as to remove the features which enable abuse—while still retaining the intended medical benefit when the drug is used properly. To do this, Pisgah has modified the active ingredient in the drug product to have properties which are difficult to extract from the dosage form (the pill) and to yield a drug substance that is ineffective when used illicitly in "alternate routes of administration." This chemical and physical selectivity imparted to the drug substance—the active pharmaceutical ingredient (API), now enables drug product manufacturers to prepare specialty pharmaceuticals with highly refined features and benefits.    

Pisgah's president and CEO, Bill Bristol commented, "The broad applicability of these innovations offers a new hope for defeating the drug abuse cycle while revitalizing an underserved market." Indeed, Pisgah's approach allows for advancement on many fronts supporting abuse-deterrent product development for a range of pain, AD(H)D and bariatric medications. As bureaucracy and regulations have strangled an otherwise vibrant drug development industry, Pisgah's inventions offer a scientific underpinning to the FDA's objectives to reduce drug abuse and provide a predictable and viable financial mechanism to potential patent licensees.

Bristol further commented, "Tangible accomplishments such as allowed patents, animal studies and IND filings serve to further validate the technology and make it a credible business venture with a high probability of success." And, Pisgah is doing their part to deliver on a complex set of expectations by internally funding the product development work on an abuse deterrent hydrocodone product. As each step of product development progresses, new quality standards are achieved and the unique features and benefits of the technology are confirmed. Bristol's only lament is the absence of multiple products being developed simultaneously in order to hasten these valuable products to market. He concedes that large pharmaceutical companies are hesitant to commit to new opportunities until essentially all risks are removed. This reluctance is enhanced by global market uncertainties and the poor business climate created by enormous government deficits. Pisgah's product development activities are self-funded and clearly reflect this company's commitment to improving the safety of beneficial medications while pursuing an entrepreneurial return. As Pisgah continues on its progression of patent allowances and product development, it's their intention to collaborate in licensing arrangements to help fill empty pipelines.

For more information or to discuss the available opportunities, contact:

Todd Stamps
Business and Market Development
803-212-8224

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com


'/>"/>
SOURCE Pisgah Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
2. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
3. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
4. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
5. Projecis Signs "Top 5" Worldwide Generic Drug Maker and Niche European CRO as Sales Climb for Software Company
6. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
7. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
8. World Alzheimers Report 2012 Reveals Stigma and Social Exclusion are Major Barriers for People With Dementia and Their Carers
9. Disney World Theme Parks Latest Addition
10. ClosedWon Launches QuickQuote at Dreamforce 2012 on Salesforce.coms AppExchange, the Worlds Most Popular Cloud Marketplace for Social Apps for Business
11. U.S. Veterans Discover Koreas World-Class Health and Wellness Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
Breaking Medicine News(10 mins):